Eye Drop Production Siegfried Expands Production Capacity for Ophthalmic Drugs in El Masnou

Source: Siegfried 1 min Reading Time

Related Vendors

To meet rising global demand, Siegfried is significantly expanding its sterile eye drop capacity at its El Masnou site near Barcelona. The move reinforces its role as a key supplier for the European ophthalmic market and complements its U.S. operations in Irvine. The new capacity will be available from 2027.

Established in 1925, Siegfried’s El Masnou site has a century long expertise in pharmaceutical manufacturing with deep expertise in ophthalmic formulations. (Source:  Siegfried)
Established in 1925, Siegfried’s El Masnou site has a century long expertise in pharmaceutical manufacturing with deep expertise in ophthalmic formulations.
(Source: Siegfried)

Contract manufacturer Siegfried announced a further expansion of its ophthalmic drug manufacturing site in El Masnou near Barcelona, Spain. The latest expansion will significantly increase the site’s sterile eye drop manufacturing capacity, in response to growing customer demand. The new capacity will be available for customers beginning in 2027.

This additional expansion complements the company’s ongoing initiative to increase production capacity for sterile eye care ointments, which is expected to be available to customers by 2026. It also includes the acquisition of state-of-the-art equipment compliant with the European Union’s Annex 1 regulations for the manufacture of sterile medicinal products.

Marcel Imwinkelried, CEO: “We see continued strong demand for ophthalmic products and the expansion of our El Masnou site will provide valuable additional capacity for our customers. This expansion enhances our global ophthalmic manufacturing footprint and enables us, together with our ophthalmics site in Irvine, US, to effectively serve Europe and the US.”

(ID:50436289)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent